Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 03, 2022

Efficacy and Safety of Cilta-Cel in Patients With Progressive MM After Exposure to Non-Cellular BCMA-Targeting Agents



Additional Info

Disclosure statements are available on the authors' profiles:

Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents
Blood 2022 Sep 12;[EPub Ahead of Print], AD Cohen, MV Mateos, YC Cohen, P Rodriguez-Otero, B Paiva, NWCJ van de Donk, TG Martin, A Suvannasankha, KC De Braganca, C Corsale, JM Schecter, H Varsos, W Deraedt, L Wang, M Vogel, T Roccia, X Xu, P Mistry, E Zudaire, M Akram, T Nesheiwat, L Pacaud, I Avivi, J San-Miguel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading